Tilray most likely to hit ~$174
https://aicody.com/articles/stocks/tilray-inc-pharma-and-medical-pharmaceuticals-drugs-stock-analysis-rating-2018-forecast-etmze20slt9uatwk/
Company Summary
Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in ten countries spanning five continents. Tilray has reported financial results for second quarter of 2018 and six months ended June 30, 2018.
“We are very pleased with our strong start to 2018. Tilray is well-positioned to continue to pioneer the development of the global medical cannabis market and to become a leader in the adult-use cannabis market in Canada,” said Mr. Brendan Kennedy, President and Chief Executive Officer of Tilray. “In the second quarter, we generated significant revenue growth as a result of our global strategy, our multinational distribution network and our commitment to research, innovation, quality and operational excellence.
Second Quarter 2018 Financial Highlights
Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales.
Total kilogram equivalents sold increased 745 kilograms to 1,514 kilograms, or 97%, compared to the prior year.
Average net selling price per gram increased from $6.20 to $6.38 (C$8.12 to C$8.36) for the three months ended June 30, 2017 and 2018, respectively. The increase was primarily due to growth in higher potency product and extract sales, partially offset by an increase in wholesale revenues.
Net loss for the quarter was $12.8 million compared to $2.4 million for the second quarter of 2017. Net loss includes non-cash stock compensation charges of $5.6 million compared to a $35 thousand charged in the prior year period. Adjusted EBITDA was a loss of $4.7 million compared to a loss of $1.9 million the second quarter last year. The increased net loss and Adjusted EBITDA decline was primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financing and the initial public offering (“IPO”).
Business Highlights in 2018 to date:
Successfully completed IPO in July whereby 10.350 million shares of Class 2 Common Stock were sold at an initial price to the public of $17.00 per share. The Company received net proceeds of $163.6 (C$216.9) million after the underwriting discount. Net proceeds will be used to fund the build out of cultivation and processing capacity, repay outstanding principal and interest under the Privateer Holdings debt facilities, and for future acquisitions and working capital.
Prior to the IPO, completed Series A funding of $55.0 (C$69.2) million from leading institutional investors.
Signed agreements to supply cannabis to adult-use consumers in seven Canadian provinces and territories (British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory and the Northwest Territories).
Entered into a strategic agreement with Sandoz Canada, a division of Novartis, to collaborate on the creation and sale of co-branded and co-developed non-combustible medical cannabis products.
Signed agreement with Shoppers Drug Mart Inc., Canada’s largest pharmacy chain with more than 1,200 pharmacies and expect to supply Tilray products following approval of Shoppers’ application to become a Licensed Producer.
Signed binding letter of intent with Pharmasave, one of Canada’s leading independent pharmacy chains with more than 650 pharmacies, which Tilray anticipates will allow it to supply Pharmasave stores with Tilray products contingent upon a change in laws that permits Canadian pharmacies to distribute medical cannabis to patients.
Completed exports to Argentina, South Africa and the United Kingdom, making Tilray products available in 11 countries on five continents.
Launched High Park Holdings Ltd., Tilray’s wholly owned subsidiary formed to serve the pending adult-use market in Canada with a broad-based portfolio of cannabis brands and products.
Announced the launch of the CANACA™ brand, a new cannabis brand celebrating Canadian roots, values and this historical moment in Canada as the country becomes the world’s first G7 nation to federally legalize cannabis through adult-use legalization.
Announced clinical study results of Tilray® 2:100 product showed promise in Canada’s first pediatric study of mixed THC/CBD medical cannabis oil for children with drug-resistant epilepsy.
Statistics
Shares Outstanding: 76.5M
Avg Daily Vol: 8.5M
Market Cap: 14.08B
52-Week High: $151.18
52-Week Low: $20.10
Forward PE: NA
Annual Div/Dividend Yield: $0.00 / 0.00%
Annual Rev: 23.1M
Inst Own: 0.0%
1-Month Return: NA
3-Month Return: NA
Next Earnings Report Date: 08/29/2018
Earnings ESP: -0.18
Revenue Per Employee: $85,912
Money Flow Ratio: 1.08%
Profitability
Revenue Growth: 62.5% (Sector Average 3.3%)
Gross Margin: 53.0% (Sector Average 62.4%)
Return on Equity: NA (Sector Average -19.2%)
Net Margin: -52.9% (Sector Average -10.4%)
Debt
Current Ratio: 1.1 (Sector Average 2.9)
Debt-to-Capital: 230.5% (Sector Average 25.8%)
Interest Funding: -12.5% (Sector Average 0.3%)
Interest Coverage: -11.6 (Sector Average -4.7)
Dividend
Dividend Growth: NA (Sector Average 5.5%)
Dividend Payout: NA (Sector Average 66.7%)
Dividend Coverage: NA (Sector Average 2.1)
Dividend Yield: NA (Sector Average 0.00%)
Top Peer Companies
Akcea Therapeutics Inc (AKCA)
Akorn Inc (AKRX)
American Cannabis Company Inc (OTCMKTS: AMMJ)
Amphastar Pharmaceuticals Inc (AMPH)
Aphira Inc (TSE: APH)
Aurora Cannabis Inc (TSE: ACB)
Cambrex Corp (CBM)
CannaRoyalty Corp (CNSX: CRZ)
Canopy Growth Corp (CGC)
Corcept Therapeutics Inc (CORT)
Cronos Group Inc (CRON)
Emergent BioSolutions Inc (EBS)
Hydropothecary Corp (TSE: HEXO)
Innoviva Inc (INVA)
Maricann Group Inc (CNSX: MARI)
Medmen Enterprises Inc (CNSX: MMEN)
MedReleaf Corp (MEDFF)
OPKO Health Inc (OPK)
Pacira Pharmaceuticals Inc (PCRX)
Theravance Biopharma Inc (TBPH)
VIVO Cannabis Inc (ABCCF)
12 Month Price Target
Mean: USD$115.05
High: USD$174.33
Low: USD$90.32
Revenue Growth
Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales.
Earnings Surprise
Positive (+18.4%)
Company Summary
Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in ten countries spanning five continents. Tilray has reported financial results for second quarter of 2018 and six months ended June 30, 2018.
“We are very pleased with our strong start to 2018. Tilray is well-positioned to continue to pioneer the development of the global medical cannabis market and to become a leader in the adult-use cannabis market in Canada,” said Mr. Brendan Kennedy, President and Chief Executive Officer of Tilray. “In the second quarter, we generated significant revenue growth as a result of our global strategy, our multinational distribution network and our commitment to research, innovation, quality and operational excellence.
Second Quarter 2018 Financial Highlights
Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales.
Total kilogram equivalents sold increased 745 kilograms to 1,514 kilograms, or 97%, compared to the prior year.
Average net selling price per gram increased from $6.20 to $6.38 (C$8.12 to C$8.36) for the three months ended June 30, 2017 and 2018, respectively. The increase was primarily due to growth in higher potency product and extract sales, partially offset by an increase in wholesale revenues.
Net loss for the quarter was $12.8 million compared to $2.4 million for the second quarter of 2017. Net loss includes non-cash stock compensation charges of $5.6 million compared to a $35 thousand charged in the prior year period. Adjusted EBITDA was a loss of $4.7 million compared to a loss of $1.9 million the second quarter last year. The increased net loss and Adjusted EBITDA decline was primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financing and the initial public offering (“IPO”).
Business Highlights in 2018 to date:
Successfully completed IPO in July whereby 10.350 million shares of Class 2 Common Stock were sold at an initial price to the public of $17.00 per share. The Company received net proceeds of $163.6 (C$216.9) million after the underwriting discount. Net proceeds will be used to fund the build out of cultivation and processing capacity, repay outstanding principal and interest under the Privateer Holdings debt facilities, and for future acquisitions and working capital.
Prior to the IPO, completed Series A funding of $55.0 (C$69.2) million from leading institutional investors.
Signed agreements to supply cannabis to adult-use consumers in seven Canadian provinces and territories (British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory and the Northwest Territories).
Entered into a strategic agreement with Sandoz Canada, a division of Novartis, to collaborate on the creation and sale of co-branded and co-developed non-combustible medical cannabis products.
Signed agreement with Shoppers Drug Mart Inc., Canada’s largest pharmacy chain with more than 1,200 pharmacies and expect to supply Tilray products following approval of Shoppers’ application to become a Licensed Producer.
Signed binding letter of intent with Pharmasave, one of Canada’s leading independent pharmacy chains with more than 650 pharmacies, which Tilray anticipates will allow it to supply Pharmasave stores with Tilray products contingent upon a change in laws that permits Canadian pharmacies to distribute medical cannabis to patients.
Completed exports to Argentina, South Africa and the United Kingdom, making Tilray products available in 11 countries on five continents.
Launched High Park Holdings Ltd., Tilray’s wholly owned subsidiary formed to serve the pending adult-use market in Canada with a broad-based portfolio of cannabis brands and products.
Announced the launch of the CANACA™ brand, a new cannabis brand celebrating Canadian roots, values and this historical moment in Canada as the country becomes the world’s first G7 nation to federally legalize cannabis through adult-use legalization.
Announced clinical study results of Tilray® 2:100 product showed promise in Canada’s first pediatric study of mixed THC/CBD medical cannabis oil for children with drug-resistant epilepsy.
Statistics
Shares Outstanding: 76.5M
Avg Daily Vol: 8.5M
Market Cap: 14.08B
52-Week High: $151.18
52-Week Low: $20.10
Forward PE: NA
Annual Div/Dividend Yield: $0.00 / 0.00%
Annual Rev: 23.1M
Inst Own: 0.0%
1-Month Return: NA
3-Month Return: NA
Next Earnings Report Date: 08/29/2018
Earnings ESP: -0.18
Revenue Per Employee: $85,912
Money Flow Ratio: 1.08%
Profitability
Revenue Growth: 62.5% (Sector Average 3.3%)
Gross Margin: 53.0% (Sector Average 62.4%)
Return on Equity: NA (Sector Average -19.2%)
Net Margin: -52.9% (Sector Average -10.4%)
Debt
Current Ratio: 1.1 (Sector Average 2.9)
Debt-to-Capital: 230.5% (Sector Average 25.8%)
Interest Funding: -12.5% (Sector Average 0.3%)
Interest Coverage: -11.6 (Sector Average -4.7)
Dividend
Dividend Growth: NA (Sector Average 5.5%)
Dividend Payout: NA (Sector Average 66.7%)
Dividend Coverage: NA (Sector Average 2.1)
Dividend Yield: NA (Sector Average 0.00%)
Top Peer Companies
Akcea Therapeutics Inc (AKCA)
Akorn Inc (AKRX)
American Cannabis Company Inc (OTCMKTS: AMMJ)
Amphastar Pharmaceuticals Inc (AMPH)
Aphira Inc (TSE: APH)
Aurora Cannabis Inc (TSE: ACB)
Cambrex Corp (CBM)
CannaRoyalty Corp (CNSX: CRZ)
Canopy Growth Corp (CGC)
Corcept Therapeutics Inc (CORT)
Cronos Group Inc (CRON)
Emergent BioSolutions Inc (EBS)
Hydropothecary Corp (TSE: HEXO)
Innoviva Inc (INVA)
Maricann Group Inc (CNSX: MARI)
Medmen Enterprises Inc (CNSX: MMEN)
MedReleaf Corp (MEDFF)
OPKO Health Inc (OPK)
Pacira Pharmaceuticals Inc (PCRX)
Theravance Biopharma Inc (TBPH)
VIVO Cannabis Inc (ABCCF)
12 Month Price Target
Mean: USD$115.05
High: USD$174.33
Low: USD$90.32
Revenue Growth
Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales.
Earnings Surprise
Positive (+18.4%)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.